Literature DB >> 21104436

Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma.

Arzu Ergen1, Onder Kılıcoglu, Harzem Ozger, Bedia Agachan, Turgay Isbir.   

Abstract

Paraoxonase is an HDL-associated enzyme that plays a preventive role against oxidative stres. Previous studies suggested that involved an amino acid substitution at position 192 gives rise to two alloenzymes with a low activity (Q allele) and a high activity (R allele) towards paraoxon. There also exists a second polymorphism of the human PON1 gene affecting amino acid 55, giving rise to a leucine (L-allele) substitution for methionine (M-allele). PON1 gene polymorphisms were studied in 50 patients with osteosarcoma and 50 healthy controls. Paraoxonase genotypes were determined by PCR-RFLP. We found a reduction in the frequency of PON1 192 R allele in patients (P=0.015). Besides, PON1 192 wild type QQ genotype (P=0.015) and PON1 55 wild type L allele (P=0.001) were higher in patients compared to healthy controls. PON1 192 QQ genotype was associated with osteosarcoma in multivariate logistic regression analysis. Our findings have suggested that PON1 192 wild type genotypes may be associated with a risk of developing osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104436     DOI: 10.1007/s11033-010-0538-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  25 in total

1.  Xenobiotic gene polymorphisms and susceptibility to multiple myeloma.

Authors:  Lisa F Lincz; Ian Kerridge; Fiona E Scorgie; Michael Bailey; Arno Enno; Andrew Spencer
Journal:  Haematologica       Date:  2004-05       Impact factor: 9.941

Review 2.  Free radicals and carcinogenesis.

Authors:  B D Goldstein; G Witz
Journal:  Free Radic Res Commun       Date:  1990

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort.

Authors:  Victoria L Stevens; Carmen Rodriguez; Alexandre L Pavluck; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

5.  Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.

Authors:  Cinzia Antognelli; Luigi Mearini; Vincenzo Nicola Talesa; Antonella Giannantoni; Ettore Mearini
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

6.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.

Authors:  D M Shih; L Gu; Y R Xia; M Navab; W F Li; S Hama; L W Castellani; C E Furlong; L G Costa; A M Fogelman; A J Lusis
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

Review 7.  Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain).

Authors:  Paloma Cejas; Enrique Casado; Cristobal Belda-Iniesta; Javier De Castro; Enrique Espinosa; Andrés Redondo; María Sereno; Miguel A García-Cabezas; Juan A F Vara; Aurora Domínguez-Cáceres; Rosario Perona; Manuel González-Barón
Journal:  Cancer Causes Control       Date:  2004-09       Impact factor: 2.506

8.  Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.

Authors:  Lisa Gallicchio; Meghan A McSorley; Craig J Newschaffer; Han-Yao Huang; Lucy W Thuita; Sandra C Hoffman; Kathy J Helzlsouer
Journal:  Cancer Detect Prev       Date:  2007-04-10

9.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.

Authors:  J Ruiz; H Blanché; R W James; M C Garin; C Vaisse; G Charpentier; N Cohen; A Morabia; P Passa; P Froguel
Journal:  Lancet       Date:  1995-09-30       Impact factor: 79.321

Review 10.  Reactive oxygen species in oncogenic transformation.

Authors:  L Behrend; G Henderson; R M Zwacka
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

View more
  6 in total

1.  Association between rs662 (A > G) and rs854560 (A > T) polymorphisms in PON1 gene and the susceptibility for psoriasis in mestizo population of Western Mexico.

Authors:  A A Hernández-Collazo; Oscar Pérez-Méndez; Victoria López-Olmos; V Delgado-Rizo; J F Muñoz-Valle; Erika Martínez-López; D G Villanueva-Quintero; Carolina Domínguez-Díaz; Mary Fafutis-Morris; Anabell Alvarado-Navarro
Journal:  Mol Biol Rep       Date:  2020-12-07       Impact factor: 2.316

2.  Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.

Authors:  Dai-Hua Fang; Cong-Hai Fan; Qiang Ji; Bo-Xiang Qi; Juan Li; Lu Wang
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

Review 3.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

4.  Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk.

Authors:  Yu He; XinJun Liang; ChunQing Meng; ZengWu Shao; Yong Gao; Qiang Wu; JianXiang Liu; Hong Wang; ShuHua Yang
Journal:  Int Orthop       Date:  2014-05-31       Impact factor: 3.075

5.  Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies.

Authors:  Lei Chen; Wei Lu; Lu Fang; Hu Xiong; Xun Wu; Meng Zhang; Song Wu; Dexin Yu
Journal:  Onco Targets Ther       Date:  2016-03-04       Impact factor: 4.147

6.  Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Authors:  Clara Benna; Andrea Simioni; Sandro Pasquali; Davide De Boni; Senthilkumar Rajendran; Giovanna Spiro; Chiara Colombo; Calogero Virgone; Steven G DuBois; Alessandro Gronchi; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Oncotarget       Date:  2018-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.